Hemophilia A and B coagulation defects, which are caused by deficiencies of Factor VIII and Factor IX, respectively, can be bypassed by administration of recombinant Factor VIIa. However, the short ...

A literatur survey concludes that the efficacy of recombinant activated factor VII administered by continuous infusion (rFVIIa CI) in patients with congenital hemophilia with inhibitors or congenital ...

Hematology researchers have further refined how a treatment currently used on an urgent basis to control bleeding in hemophilia patients holds promise as a preventive treatment as well. A study in ...

Hematology researchers have further refined how a treatment currently used on an urgent basis to control bleeding in hemophilia patients holds promise as a preventive treatment as well. A study in ...

(RTTNews) - The board of Sino Biopharmaceutical (SBMFF) announced that the Group's self-developed Recombinant Human Coagulation Factor VIIa N01 for Injection, with brand name: Anqixin - has been ...

Control of variceal bleeding is particularly difficult in patients with advanced liver disease, owing to their impaired production of coagulation factor VII. Bosch and colleagues studied whether ...

The use of factor VIIa (recombinant) as a hemostatic agent is attractive for several reasons. Because it is cloned and expressed in baby hamster kidney cells and purified without use of human serum or ...

Villar and colleagues [10] determined the pharmacokinetics of factor VIIa (recombinant) in 12 children (age 2–12 years) and 6 adults with hemophilia A, with and without inhibitors to factor VIII, ...